BioLight Life Sciences Investments Ltd. will distribute IOPtima’s IOPtiMate laser eye surgery system in Hong Kong and Macao, with a purchase commitment of at least nine systems. IOPtiMate is based on CO2 laser technology and enables filtration surgery, which treats glaucoma without penetrating the inner part of the eyeball. Compared with alternatives, this allows substantial reductions in postoperative complications and use of eye drops, according to BioLight. A leading medical center in Hong Kong recently purchased the system, while another is using IOPtiMate on a trial basis. “Entering into a strategic distribution agreement in Hong Kong and Macao is an additional significant advancement in our plan to penetrate developing markets in Asia, where there is no available solution for a large population of patients,” said BioLight CEO Suzana Nahum-Zilberberg. Earlier this year BioLight and IOPtima reached a distribution agreement for China with a purchase commitment of 100 systems. For more information, visit www.bio-light.co.il.